Rare Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others), By Trait Type (Inherited v/s Acquired), By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others), By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others), By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others), By End User (Hospitals & Clinics, Academic & Research Institutes, Others), By company and By Region
The global rare disease diagnostics market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the growing incidence of rare disorders, adoption of advanced technology, and increase in investments in R&D are impelling the growth of the market. Rare diseases or orphan diseases is any disease that affects a small percentage of the population. The other factors supporting the market’s growth are, increasing government initiatives for spreading awareness, expanding patient registry for rare diseases, declining sequencing cost, rising geriatric population, the growing launch of programs & new product development in rare disease diagnosis, and rise in research and development activities.
The rising incidence of rare disorders will fuel the market growth.
Rare diseases are not rarer as there are many people who are suffering from the disease. They affect more people than the combination of AIDS & Cancer. For instance, as per the European Journal of Human Genetics, the number of people living with a rare disease is estimated at 300 million across the globe. Owing to the rise in the number of people suffering from rare diseases such as Agammaglobulinemia, Goodpasture Syndrome, Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis), Leukocyte Adhesion Deficiency, Pediatric Bruton Agammaglobulinemia, Pediatric Severe Combined Immunodeficiency, Schnitzler Syndrome and others, the surge in demand for the diagnosis is bolstering the growth of the market.
Technological Advancements in Disease Diagnosis
The rise in the adoption of advanced technology in the field of rare diseases diagnostic is augmenting the growth of the market. New innovative technologies and advancements such as artificial intelligence (AI), NGS-based testing, and automation technology are assisting in reducing time and cost and enabling more accurate diagnosis when compared to standard manual analysis. For instance, increase in the adoption of the Whole Exome Sequencing (WES) genetic testing tool. The technique aims only at exons, which make 1-2% of the whole genome and include 80% of all disease-causing mutations.
Rising Awareness of diagnosis of rare diseases
Early diagnosis of rare diseases is essential as it can help people to treat these conditions timely without suffering. Thus, the rise in awareness about rare diseases among the general public and patients is facilitating the growth of the market. Various initiatives by government and non-government organizations are taken to make people aware of the early diagnosis and treatment of the disease. For instance, every year, rare diseases day at NIH takes place, which aims to raise awareness about rare diseases and the impact they have on patient’s lives.
Market Segmentation
The global rare disease diagnostics market is segmented into indication, trait type, test type, technology, sample type, end user, and company. Based on indication, the market is divided into gastroenterology disease, endocrine & metabolism disorders disease, cardiovascular disorders, hematology & oncology disease, and others. Based on trait type, the market is divided into inherited and acquired. Based on test type, the market is segmented into genetic tests, general lab tests, diagnostic imaging, and others. Based on technology, the market is divided into next-generation sequencing, whole genome sequencing, whole exome sequencing, microarrays, and others. Based on sample type, the market is divided into DNA samples, blood sample, saliva samples, and others. Based on end-user, the market is divided into hospitals & clinics, academic & research institutes, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising occurrences of rare diseases in the country.
Market Players
Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation are some of the leading companies operating in the market.
Report Scope:
In this report, global rare disease diagnostics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Global Rare Disease Diagnostics Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
The rising incidence of rare disorders will fuel the market growth.
Rare diseases are not rarer as there are many people who are suffering from the disease. They affect more people than the combination of AIDS & Cancer. For instance, as per the European Journal of Human Genetics, the number of people living with a rare disease is estimated at 300 million across the globe. Owing to the rise in the number of people suffering from rare diseases such as Agammaglobulinemia, Goodpasture Syndrome, Granulomatosis with Polyangiitis (GPA, formerly Wegener Granulomatosis), Leukocyte Adhesion Deficiency, Pediatric Bruton Agammaglobulinemia, Pediatric Severe Combined Immunodeficiency, Schnitzler Syndrome and others, the surge in demand for the diagnosis is bolstering the growth of the market.
Technological Advancements in Disease Diagnosis
The rise in the adoption of advanced technology in the field of rare diseases diagnostic is augmenting the growth of the market. New innovative technologies and advancements such as artificial intelligence (AI), NGS-based testing, and automation technology are assisting in reducing time and cost and enabling more accurate diagnosis when compared to standard manual analysis. For instance, increase in the adoption of the Whole Exome Sequencing (WES) genetic testing tool. The technique aims only at exons, which make 1-2% of the whole genome and include 80% of all disease-causing mutations.
Rising Awareness of diagnosis of rare diseases
Early diagnosis of rare diseases is essential as it can help people to treat these conditions timely without suffering. Thus, the rise in awareness about rare diseases among the general public and patients is facilitating the growth of the market. Various initiatives by government and non-government organizations are taken to make people aware of the early diagnosis and treatment of the disease. For instance, every year, rare diseases day at NIH takes place, which aims to raise awareness about rare diseases and the impact they have on patient’s lives.
Market Segmentation
The global rare disease diagnostics market is segmented into indication, trait type, test type, technology, sample type, end user, and company. Based on indication, the market is divided into gastroenterology disease, endocrine & metabolism disorders disease, cardiovascular disorders, hematology & oncology disease, and others. Based on trait type, the market is divided into inherited and acquired. Based on test type, the market is segmented into genetic tests, general lab tests, diagnostic imaging, and others. Based on technology, the market is divided into next-generation sequencing, whole genome sequencing, whole exome sequencing, microarrays, and others. Based on sample type, the market is divided into DNA samples, blood sample, saliva samples, and others. Based on end-user, the market is divided into hospitals & clinics, academic & research institutes, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising occurrences of rare diseases in the country.
Market Players
Agilent Technologies, Inc., Illumina, Inc., QIAGEN NV, PerkinElmer, Inc, Quest Diagnostics, Inc., CENTOGENE N.V., 23andMe, Inc., 3billion, Inc., Eurofins Scientific SE, and Invitae Corporation are some of the leading companies operating in the market.
Report Scope:
In this report, global rare disease diagnostics market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Rare Disease Diagnostics Market, By Indication:
- Gastroenterology Disease
- Endocrine & Metabolism Disorders Disease
- Cardiovascular Disorders
- Hematology & Oncology Disease
- Others
- Rare Disease Diagnostics Market, By Trait Type:
- Inherited
- Acquired
- Rare Disease Diagnostics Market, By Test Type:
- Genetic Tests
- General Lab Tests
- Diagnostic Imaging
- Others
- Rare Disease Diagnostics Market, By Technology:
- Next Generation Sequencing
- Whole Genome Sequencing
- Whole Exome Sequencing
- Microarrays
- Others
- Rare Disease Diagnostics Market, By Sample Type:
- DNA Sample
- Blood Sample
- Saliva Sample
- Others
- Rare Disease Diagnostics Market, By End User:
- Hospitals & Clinics
- Academic & Research Institutes
- Others
- Rare Disease Diagnostics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Global Rare Disease Diagnostics Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL RARE DISEASE DIAGNOSTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others)
6.2.2. By Trait Type (Inherited v/s Acquired)
6.2.3. By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others)
6.2.4. By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others)
6.2.5. By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others)
6.2.6. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
6.2.7. By Region
6.2.8. By Company (2021)
6.3. Market Map
7. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Trait Type
7.2.3. By Test Type
7.2.4. By Technology
7.2.5. By Sample Type
7.2.6. By End User
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States Rare Disease Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Trait Type
7.3.1.2.3. By Test Type
7.3.1.2.4. By Technology
7.3.1.2.5. By Sample Type
7.3.1.2.6. By End User
7.3.2. Canada Rare Disease Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Trait Type
7.3.2.2.3. By Test Type
7.3.2.2.4. By Technology
7.3.2.2.5. By Sample Type
7.3.2.2.6. By End User
7.3.3. Mexico Rare Disease Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Trait Type
7.3.3.2.3. By Test Type
7.3.3.2.4. By Technology
7.3.3.2.5. By Sample Type
7.3.3.2.6. By End User
8. EUROPE RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Trait Type
8.2.3. By Test Type
8.2.4. By Technology
8.2.5. By Sample Type
8.2.6. By End User
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. France Rare Disease Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Trait Type
8.3.1.2.3. By Test Type
8.3.1.2.4. By Technology
8.3.1.2.5. By Sample Type
8.3.1.2.6. By End User
8.3.2. Germany Rare Disease Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Trait Type
8.3.2.2.3. By Test Type
8.3.2.2.4. By Technology
8.3.2.2.5. By Sample Type
8.3.2.2.6. By End User
8.3.3. United Kingdom Rare Disease Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Trait Type
8.3.3.2.3. By Test Type
8.3.3.2.4. By Technology
8.3.3.2.5. By Sample Type
8.3.3.2.6. By End User
8.3.4. Italy Rare Disease Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By Trait Type
8.3.4.2.3. By Test Type
8.3.4.2.4. By Technology
8.3.4.2.5. By Sample Type
8.3.4.2.6. By End User
8.3.5. Spain Rare Disease Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By Trait Type
8.3.5.2.3. By Test Type
8.3.5.2.4. By Technology
8.3.5.2.5. By Sample Type
8.3.5.2.6. By End User
9. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Trait Type
9.2.3. By Test Type
9.2.4. By Technology
9.2.5. By Sample Type
9.2.6. By End User
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Rare Disease Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Trait Type
9.3.1.2.3. By Test Type
9.3.1.2.4. By Technology
9.3.1.2.5. By Sample Type
9.3.1.2.6. By End User
9.3.2. India Rare Disease Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Trait Type
9.3.2.2.3. By Test Type
9.3.2.2.4. By Technology
9.3.2.2.5. By Sample Type
9.3.2.2.6. By End User
9.3.3. Japan Rare Disease Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Trait Type
9.3.3.2.3. By Test Type
9.3.3.2.4. By Technology
9.3.3.2.5. By Sample Type
9.3.3.2.6. By End User
9.3.4. South Korea Rare Disease Diagnostics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Trait Type
9.3.4.2.3. By Test Type
9.3.4.2.4. By Technology
9.3.4.2.5. By Sample Type
9.3.4.2.6. By End User
9.3.5. Australia Rare Disease Diagnostics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Trait Type
9.3.5.2.3. By Test Type
9.3.5.2.4. By Technology
9.3.5.2.5. By Sample Type
9.3.5.2.6. By End User
10. SOUTH AMERICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Trait Type
10.2.3. By Test Type
10.2.4. By Technology
10.2.5. By Sample Type
10.2.6. By End User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Rare Disease Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Trait Type
10.3.1.2.3. By Test Type
10.3.1.2.4. By Technology
10.3.1.2.5. By Sample Type
10.3.1.2.6. By End User
10.3.2. Argentina Rare Disease Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Trait Type
10.3.2.2.3. By Test Type
10.3.2.2.4. By Technology
10.3.2.2.5. By Sample Type
10.3.2.2.6. By End User
10.3.3. Colombia Rare Disease Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Trait Type
10.3.3.2.3. By Test Type
10.3.3.2.4. By Technology
10.3.3.2.5. By Sample Type
10.3.3.2.6. By End User
11. MIDDLE EAST AND AFRICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Trait Type
11.2.3. By Test Type
11.2.4. By Technology
11.2.5. By Sample Type
11.2.6. By End User
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Rare Disease Diagnostics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Trait Type
11.3.1.2.3. By Test Type
11.3.1.2.4. By Technology
11.3.1.2.5. By Sample Type
11.3.1.2.6. By End User
11.3.2. Saudi Arabia Rare Disease Diagnostics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Trait Type
11.3.2.2.3. By Test Type
11.3.2.2.4. By Technology
11.3.2.2.5. By Sample Type
11.3.2.2.6. By End User
11.3.3. UAE Rare Disease Diagnostics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Trait Type
11.3.3.2.3. By Test Type
11.3.3.2.4. By Technology
11.3.3.2.5. By Sample Type
11.3.3.2.6. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE (INCLUSIVE OF SWOT ANALYSIS)
14.1. Agilent Technologies, Inc.
14.2. Illumina, Inc.
14.3. QIAGEN NV
14.4. PerkinElmer, Inc
14.5. Quest Diagnostics, Inc.
14.6. CENTOGENE N.V.
14.7. 23andMe, Inc.
14.8. 3billion, Inc.
14.9. Eurofins Scientific SE
14.10. Invitae Corporation
15. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL RARE DISEASE DIAGNOSTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication (Gastroenterology Disease, Endocrine & Metabolism Disorders Disease, Cardiovascular Disorders, Hematology & Oncology Disease, Others)
6.2.2. By Trait Type (Inherited v/s Acquired)
6.2.3. By Test Type (Genetic Tests, General Lab Tests, Diagnostic Imaging, Others)
6.2.4. By Technology (Next Generation Sequencing, Whole Genome Sequencing, Whole Exome Sequencing, Microarrays, Others)
6.2.5. By Sample Type (DNA Sample, Blood Sample, Saliva Sample, Others)
6.2.6. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
6.2.7. By Region
6.2.8. By Company (2021)
6.3. Market Map
7. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Trait Type
7.2.3. By Test Type
7.2.4. By Technology
7.2.5. By Sample Type
7.2.6. By End User
7.2.7. By Country
7.3. North America: Country Analysis
7.3.1. United States Rare Disease Diagnostics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.1.2.2. By Trait Type
7.3.1.2.3. By Test Type
7.3.1.2.4. By Technology
7.3.1.2.5. By Sample Type
7.3.1.2.6. By End User
7.3.2. Canada Rare Disease Diagnostics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.2.2.2. By Trait Type
7.3.2.2.3. By Test Type
7.3.2.2.4. By Technology
7.3.2.2.5. By Sample Type
7.3.2.2.6. By End User
7.3.3. Mexico Rare Disease Diagnostics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.3.2.2. By Trait Type
7.3.3.2.3. By Test Type
7.3.3.2.4. By Technology
7.3.3.2.5. By Sample Type
7.3.3.2.6. By End User
8. EUROPE RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Trait Type
8.2.3. By Test Type
8.2.4. By Technology
8.2.5. By Sample Type
8.2.6. By End User
8.2.7. By Country
8.3. Europe: Country Analysis
8.3.1. France Rare Disease Diagnostics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.1.2.2. By Trait Type
8.3.1.2.3. By Test Type
8.3.1.2.4. By Technology
8.3.1.2.5. By Sample Type
8.3.1.2.6. By End User
8.3.2. Germany Rare Disease Diagnostics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.2.2.2. By Trait Type
8.3.2.2.3. By Test Type
8.3.2.2.4. By Technology
8.3.2.2.5. By Sample Type
8.3.2.2.6. By End User
8.3.3. United Kingdom Rare Disease Diagnostics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.3.2.2. By Trait Type
8.3.3.2.3. By Test Type
8.3.3.2.4. By Technology
8.3.3.2.5. By Sample Type
8.3.3.2.6. By End User
8.3.4. Italy Rare Disease Diagnostics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.4.2.2. By Trait Type
8.3.4.2.3. By Test Type
8.3.4.2.4. By Technology
8.3.4.2.5. By Sample Type
8.3.4.2.6. By End User
8.3.5. Spain Rare Disease Diagnostics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
8.3.5.2.2. By Trait Type
8.3.5.2.3. By Test Type
8.3.5.2.4. By Technology
8.3.5.2.5. By Sample Type
8.3.5.2.6. By End User
9. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Trait Type
9.2.3. By Test Type
9.2.4. By Technology
9.2.5. By Sample Type
9.2.6. By End User
9.2.7. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Rare Disease Diagnostics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.1.2.2. By Trait Type
9.3.1.2.3. By Test Type
9.3.1.2.4. By Technology
9.3.1.2.5. By Sample Type
9.3.1.2.6. By End User
9.3.2. India Rare Disease Diagnostics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.2.2.2. By Trait Type
9.3.2.2.3. By Test Type
9.3.2.2.4. By Technology
9.3.2.2.5. By Sample Type
9.3.2.2.6. By End User
9.3.3. Japan Rare Disease Diagnostics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
9.3.3.2.2. By Trait Type
9.3.3.2.3. By Test Type
9.3.3.2.4. By Technology
9.3.3.2.5. By Sample Type
9.3.3.2.6. By End User
9.3.4. South Korea Rare Disease Diagnostics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Indication
9.3.4.2.2. By Trait Type
9.3.4.2.3. By Test Type
9.3.4.2.4. By Technology
9.3.4.2.5. By Sample Type
9.3.4.2.6. By End User
9.3.5. Australia Rare Disease Diagnostics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Indication
9.3.5.2.2. By Trait Type
9.3.5.2.3. By Test Type
9.3.5.2.4. By Technology
9.3.5.2.5. By Sample Type
9.3.5.2.6. By End User
10. SOUTH AMERICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Trait Type
10.2.3. By Test Type
10.2.4. By Technology
10.2.5. By Sample Type
10.2.6. By End User
10.2.7. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Rare Disease Diagnostics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.1.2.2. By Trait Type
10.3.1.2.3. By Test Type
10.3.1.2.4. By Technology
10.3.1.2.5. By Sample Type
10.3.1.2.6. By End User
10.3.2. Argentina Rare Disease Diagnostics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.2.2.2. By Trait Type
10.3.2.2.3. By Test Type
10.3.2.2.4. By Technology
10.3.2.2.5. By Sample Type
10.3.2.2.6. By End User
10.3.3. Colombia Rare Disease Diagnostics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
10.3.3.2.2. By Trait Type
10.3.3.2.3. By Test Type
10.3.3.2.4. By Technology
10.3.3.2.5. By Sample Type
10.3.3.2.6. By End User
11. MIDDLE EAST AND AFRICA RARE DISEASE DIAGNOSTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Indication
11.2.2. By Trait Type
11.2.3. By Test Type
11.2.4. By Technology
11.2.5. By Sample Type
11.2.6. By End User
11.2.7. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Rare Disease Diagnostics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Indication
11.3.1.2.2. By Trait Type
11.3.1.2.3. By Test Type
11.3.1.2.4. By Technology
11.3.1.2.5. By Sample Type
11.3.1.2.6. By End User
11.3.2. Saudi Arabia Rare Disease Diagnostics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Indication
11.3.2.2.2. By Trait Type
11.3.2.2.3. By Test Type
11.3.2.2.4. By Technology
11.3.2.2.5. By Sample Type
11.3.2.2.6. By End User
11.3.3. UAE Rare Disease Diagnostics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Indication
11.3.3.2.2. By Trait Type
11.3.3.2.3. By Test Type
11.3.3.2.4. By Technology
11.3.3.2.5. By Sample Type
11.3.3.2.6. By End User
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE (INCLUSIVE OF SWOT ANALYSIS)
14.1. Agilent Technologies, Inc.
14.2. Illumina, Inc.
14.3. QIAGEN NV
14.4. PerkinElmer, Inc
14.5. Quest Diagnostics, Inc.
14.6. CENTOGENE N.V.
14.7. 23andMe, Inc.
14.8. 3billion, Inc.
14.9. Eurofins Scientific SE
14.10. Invitae Corporation
15. STRATEGIC RECOMMENDATIONS
